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Abstract: The effect of supplementation with 1% conjugated linoleic acid and 1% n-3 long 
chain polyunsaturated fatty acids (CLA/n-3) was assessed in rats. Food intake increased 
with no difference in body weights. White adipose tissue weights were reduced whereas 
brown adipose tissue and uncoupling protein-1 expression were increased. Plasma 
adiponectin, triglyceride and cholesterol levels were reduced while leptin, ghrelin and liver 
weight and lipid content were unchanged. Hypothalamic gene expression measurements 
revealed increased expression of orexigenic and decreased expression of anorexigenic 
signals. Thus, CLA/n-3 increases food intake without affecting body weight potentially 
through increasing BAT size and up-regulating UCP-1 in rats. 
Keywords:  conjugated linoleic acid; n-3 long chain polyunsaturated fatty acid; white 
adipose tissue; brown adipose tissue; hypothalamus; brain 
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1. Introduction  
There is a great deal of interest in n-3 polyunsaturated fatty acids (n-3 LC-PUFA) and conjugated 
linoleic acid (CLA) supplements that may impact on body composition and improve metabolic health. 
CLA has been reported to have widespread beneficial effects against cancer, atherosclerosis, diabetes 
and obesity [1] and has been reported to reduce body fat mass in rodents and humans [2,3]. CLA 
appears to exert its effects on fat mass by redirecting lipid metabolism from white adipose tissue 
(WAT) to other tissues, predominately the liver, by increasing activity of lipolytic pathways and 
decreasing lipogenic pathways in WAT  [3]. In mice, supplementation with the trans-10,  cis-12-
conjugated linoleic acid leads to glucose intolerance, insulin resistance and lipodystrophy and is pro-
inflammatory [4]. Conversely, supplementation with the cis-9,  trans-11-CLA increases insulin 
sensitivity via anti-inflammatory actions [5]. In obese rats a mixture of the two isomers of CLA 
improves insulin sensitivity, lowers glucose levels and increases adiponectin levels [6], while lean rats 
do not show these changes [7]. Thus, the effects of CLA in rodents are isomer specific and appear to 
differ markedly depending on species and adiposity.  
Fish oil derived n-3 LC-PUFA have been shown to reduce obesity and to have beneficial effects on 
glucose and lipid metabolism in rodents [8,9]. Human studies have also shown beneficial effects of n-3 
LC-PUFA on energy metabolism [10,11] and it has been demonstrated in mice, that n-3 LC-PUFA can 
reverse the deleterious effects of CLA on metabolism, reducing hepatomegaly and liver fat, reversing 
lipodystrophy and increasing leptin and adiponectin levels [12]. Consequently, it is possible that a 
combination of CLA plus n-3 LC-PUFA could decrease adiposity while avoiding some of the 
unwanted effects of CLA in other species. 
The impact of fatty acids on the hypothalamic centres regulating appetite and energy balance are 
only now beginning to be investigated [13,14]. The arcuate nucleus (ARC) of the hypothalamus is a 
key site for the regulation of energy homeostasis [15], and two main regulatory pathways have so far 
been identified. One pathway consists of neurons co-expressing neuropeptide Y (NPY) and agouti 
gene-related protein (AgRP), potent stimulators of food intake, while other ARC neurons co-express 
pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), which 
suppress food intake [16]. Leptin secreted by, and in proportion to WAT, activates POMC/CART 
neurons and inhibits NPY/AgRP neurons [17] resulting in inhibition of feeding and an increase in 
energy expenditure. Leptin acts via the long signalling form of leptin receptor (Ob-Rb) present in the 
ARC and the ventromedial nucleus (VMH) [18]. However, a number of shorter isoforms of the 
receptor are present and these are thought to be mainly involved in leptin transport into the brain and 
are present in the choroid plexus (CP) and brain microvessels [19,20]. Ghrelin, secreted mainly by the 
stomach acts in opposition to leptin and activates NPY/AgRP neurons [21,22] stimulating feeding and 
decreasing energy expenditure. Ghrelin acts via the growth hormone secretagogue receptors (GHS-R) 
present in the ARC and VMH. Long chain fatty acids have been reported to inhibit food intake via a 
direct effect on hypothalamic energy balance regulatory centres; decreasing  NPY and AgRP gene 
expression levels in the ARC [14,23].  
We hypothesise that supplementation with a combination of CLA and n-3 PUFA may have 
beneficial additive effects whilst avoiding the unfavorable effect on insulin sensitivity and fatty liver 
reported for CLA alone. To investigate the outcome of supplementation with CLA plus n-3 LC-PUFA Nutrients  2009, 1                                       
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on energy balance we fed normal rat chow supplemented with either 1% CLA plus 1% n-3 LC-PUFA 
or 2% vegetable oil to rats for 12 weeks and measured food intake, body weight, WAT, BAT, liver and 
muscle weights and levels of gene expression in tissues effected by the supplementation, including 
hypothalamic peptides and receptors known to be involved in energy balance. The ability of leptin to 
be transported into the brain, potentially regulating leptin signalling to the brain, was also assessed by 
measuring leptin receptor availability on the CP using [
125I]leptin binding. 
 
2. Results and Discussion  
 
2.1. Effects on Food Intake and Body Weight    
 
Supplementation with CLA plus n-3 LC-PUFA compared with control increased food intake, which 
became significant by the third week of diet (P = 0.038). Overall, the average intake of the CLA plus 
n-3 LC-PUFA group was 28 ± 0.5 vs. 24.85 ± 0.3 g per rat per day (P = 0.004) (Figure 1A). There was 
no evidence of any difference in body weight between the two groups of rats at any point during the 
experiment, with the average final weight of CLA plus n-3 LC-PUFA animals being 485 ± 6.0 g vs. 
489 ± 6.6 g for control animals (Figure 1B). 
Figure 1. A. Mean food intake of rats receiving rat chow supplemented with either 2% 
vegetable oil (control) or 2% CLA plus n-3 LC-PUFA. Mean daily intake per rat was 
calculated for each week to highlight when significant differences in food intake became 
apparent *P < 0.05 at three weeks. Daily food intake per rat was also calculated over the 12 
weeks of the experiment **P < 0.01 B. No significant difference (NS) was found in the 
body weights of the control supplementation vs. the CLA plus n-3 LC-PUFA at any of the 
measurement points during the study or in the final body weights. 
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Figure 1. Cont. 
 
2.2. Tissue Weights 
 
Retroperitoneal and subcutaneous adipose tissue weights were significantly reduced in the CLA 
plus n-3 LC- PUFA supplemented rats (–22%, P = 0.004, and –13%, P = 0.019 respectively, while 
subscapular BAT was increased by 59% (P < 0.001); there were no significant changes in the weights 
of other adipose tissue depots (Figures 2A and B). Weights of liver, gastrocnemius and soleus muscles 
were not changed by CLA plus n-3 LC-PUFA supplementation (Figures 2C and D) 
Figure 2. Effect of CLA plus n-3 LC-PUFA supplementation on tissue weights.   
A. Retroperitoneal and subcutaneous adipose tissue weights were significantly reduced in 
the CLA plus n-3 LC- PUFA supplemented rats, *P < 0.05, **P < 0.01. There were no 
significant (NS) changes in the weights of other adipose tissue depots B. Subscapular BAT 
weight was increased, ***P < 0.001. C. Weights of gastrocnemius and soleus muscles and 
D.  Liver weight was not significantly (NS) changed by CLA plus n-3 LC-PUFA 
supplementation. 
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Figure 2. Cont. 
 
 
2.3. Circulating Lipid, Glucose and Hormone Levels  
 
CLA plus n-3 LC-PUFA supplementation significantly reduced circulating levels of cholesterol and 
triglyceride but had no effect on non esterified fatty acid (NEFA) levels or non-fasted glucose levels 
(Figure 3A). Adiponectin levels were significantly reduced (P < 0.001) by CLA plus n-3 LC-PUFA 
supplementation. There were no significant changes in plasma ghrelin or plasma leptin levels   
(Figure 3B).  
Figure 3. Effect of CLA plus n-3 LC-PUFA supplementation on circulating lipid and 
hormone levels. A. CLA plus n-3 LC-PUFA supplementation significantly reduced 
circulating levels of cholesterol and triglyceride, ***P < 0.001 but had no significant (NS) 
effect on non esterified fatty acid (NEFA) levels or non-fasted glucose levels. B. 
Adiponectin levels were significantly reduced, P < 0.001 by CLA plus n-3 LC-PUFA 
supplementation. There were no significant (NS) changes in plasma ghrelin or plasma 
leptin levels. 
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Figure 3. Cont. 
 
 
2.4. Liver Lipids and Circulating Liver Enzymes 
 
There was no effect of CLA plus n-3 LC-PUFA supplementation on liver lipid content or 
circulating levels of lactate dehydrogenase (LDH) but aspartate aminotransferase (AST) activity was 
significantly higher in the CLA plus n-3 LC-PUFA supplemented animals (P = 0.049) indicating some 
degree of liver damage compared to controls (Figure 4 ). 
Figure 4. Effect of CLA plus n-3 LC-PUFA supplementation on liver lipid content and 
circulating levels of liver enzymes. Liver lipid levels and lactate dehydrogenase (LDH) 
were not significantly (NS) changed by supplementation but aspartate aminotransferase 
activity (AST) was significantly higher in the CLA plus n-3 LC-PUFA supplemented 
animals, *P < 0.05. 
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2.5. WAT, BAT and Muscle Gene Expression 
 
There was a significant increase in the expression of SREBP-1c and PPARγ in the BAT of rats 
receiving the CLA plus n-3 LC-PUFA supplementation (P  = 0.046 and P  = 0.032 respectively)   
(Figure 5A). The expression of these lipid responsive genes did not change in either the subcutaneous 
or the retroperitoneal WAT depots (Figure 5A). The gene expression of HSL and LPL were 
significantly decreased in subcutaneous WAT (P  = 0.022 and P  = 0.011 respectively) but were 
unchanged in retroperitoneal WAT. Adiponectin gene expression was increased by CLA plus n-3  
LC-PUFA supplementation in both the subcutaneous and retroperitoneal depots, but only significantly 
in the retroperitoneal depot (P = 0.09 and P = 0.014 respectively) (Figure 5B). The gene expression of 
UCP-1 in BAT was increased by CLA plus n-3 LC-PUFA supplementation (P = 0.047) (Figure 5C). 
Gastrocnemius muscle expression of GLUT4 and SREBP-1c were both down-regulated after CLA 
plus n-3 LC-PUFA supplementation compared to control (P = 0.006 and P = 0.029, respectively) 
(Figure 5D). 
Figure 5. Effect of CLA plus n-3 LC-PUFA supplementation on WAT, BAT and muscle 
gene expression. A. There was a significant increase in the expression of SREBP-1c and 
PPARγ in the BAT of rats receiving the CLA plus n-3 LC-PUFA supplementation,   
*P  < 0.05 and no significant (NS) change in either subcutaneous (Subcut) or the 
retroperitoneal (Retro) WAT. B. Hormone sensitive lipase (HSL) and lipoprotein lipase 
(LPL) were significantly decreased in subcutaneous WAT, *P < 0.05 and were not 
significantly (NS) changed in retroperitoneal WAT compared with control. Adiponectin 
gene expression was increased by CLA plus n-3 LC-PUFA supplementation in 
retroperitoneal WAT, * P < 0.05 and not significantly (NS) changed in subcutaneous WAT 
(P  = 0.09). C. UCP-1 expression in BAT was increased by CLA plus n-3 LC-PUFA 
supplementation, *P < 0.05. D. There was a significant decrease in the expression of both 
Glut4 and SREBP-1c in the gastrocnemius muscle of rats receiving the CLA plus n-3 LC-
PUFA supplementation compared with control animals, **P  < 0.01 and *P  < 0.05 
respectively. 
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Figure 5. Cont. 
 
 
2.6. Hypothalamic Gene Expression and [
125I]-Leptin Binding  
 
There was no significant change in NPY or CART gene expression in either the ARC or the VMH 
(Figure 6A & B). In the ARC, AgRP gene expression was increased (P > 0.001) after CLA plus n-3 
LC-PUFA supplementation while POMC gene expression was reduced (P = 0.007) (Figure 6C). GHS-
R was increased in the ARC (P = 0.043) but not the VMH, while Ob-Rb was unchanged in the ARC 
but significantly decreased in the VMH (P = 0.049) (Figures 7A & B). There were no significant 
changes in Ob-R expression in the CP. However, the level of specific [
125I]-leptin binding to the CP 
was increased significantly after CLA plus n-3 LC-PUFA supplementation in both the CP of the lateral 
ventricles (LV) (P = 0.031) and the dorsal third ventricle (3V) (P = 0.019) (Figure 7C). 
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Figure 6. Effect of CLA plus n-3 LC-PUFA supplementation on hypothalamic peptide 
gene expression including representative autoradiographs of the hypothalamic regions 
measured. A. There was no significant (NS) change in NPY or B. CART gene expression 
in either the arcuate nuclei (ARC), ventromedial nuclei (VMH) or paraventricular nuclei 
(PVN) after supplementation. C. AgRP gene expression was increased in the arcuate nuclei 
(ARC), ***P < 0.001 after CLA plus n-3 LC-PUFA supplementation while POMC gene 
expression was reduced, **P < 0.005.  
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Figure 7. Effect of CLA plus n-3 LC-PUFA supplementation on hypothalamic receptor 
gene expression and [
125I]leptin binding. A. GHS-R was increased in the arcuate nuclei 
(ARC), *P < 0.05 but not significantly (NS) changed in the ventromedial nuclei (VMH). B. 
Ob-Rb was not significantly (NS) changed in the ARC but significantly decreased in the 
VMH, *P < 0.05. C. There was no significant change (NS) in Ob-R expression in the 
choroid plexus (CP). The level of specific [
125I]leptin binding to the CP was increased 
significantly after CLA plus n-3 LC-PUFA supplementation in both the CP of the lateral 
ventricles (not shown) and the dorsal third ventricle, *P < 0.05. 
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2.7. Discussion 
 
In the present study, CLA plus n-3 LC-PUFA supplementation led to a depot specific reduction in 
WAT with no overall difference detectable in total body weight, an outcome that has been reported 
previously in studies with CLA and n-3 LC-PUFA alone. However, also in the present study, there was 
a significant increase in food intake in the CLA plus n-3 LC-PUFA supplemented animals. This is in 
contrast to most studies with CLA supplementation alone which have either shown decreased energy 
intake or no effect [29]. The average daily food intakes did not become significantly different until 
week three of the experiment, indicating that palatability of the diets was not a major issue. In addition, 
the loss of adiposity was not accompanied by evidence of a change in hepatic steatosis which has been 
demonstrated in other rat and mouse CLA studies [30] indicating that lipid storage was not redirected 
to the liver. Indeed there was no indication of increased liver weight or increased liver triglyceride 
demonstrated by others [31]; also there was no increase in circulating cholesterol or triglyceride 
usually associated with increased liver fat storage [31]. There was, however, an increase in circulating 
levels of AST in the supplemented rats, which may indicate that some liver damage had occurred.  
Food intake is regulated in the hypothalamus by changes in orexigenic and anorexigenic pathways 
that are modulated by peripheral signals such as leptin, ghrelin and adiponectin as well as by dietary 
composition [32]. Thus, changes in circulating hormones and the amount and composition of the diet 
can modulate peptides and receptor levels in hypothalamic nuclei involved in the regulation of intake. 
In rats, high saturated fat diets have been reported to decrease NPY expression, while high levels of 
unsaturated fats (both n-3 and n-6 LC-PUFA) decrease POMC in the ARC [13]. However, in the latter 
study, the type of fat did not alter hypothalamic gene expression on a low-fat diet. In the present study, 
the addition of relatively small concentrations of CLA plus n-3 LC-PUFA appreciably increased AgRP 
gene expression in the ARC. AgRP functions by acting as a natural antagonist at the melanocortin 4 
receptor (MC4R) blocking the action of the natural agonist α-melanocyte-stimulating hormone, a 
product of the POMC gene which is down-regulated by CLA plus n-3 LC-PUFA supplementation. The 
up-regulation of the orexigenic signal AgRP and the down-regulation of the anorexigenic POMC gene 
thus provide a dual signal to increase food intake. 
As small amounts of n-3 LC-PUFA have not been reported to produce any changes in hypothalamic 
gene expression in the hypothalamic arcuate or ventromedial nuclei in rats [13], the changes seen with 
CLA plus n-3 LC-PUFA must result either from the CLA alone or a synergistic action between CLA 
and  n-3 LC-PUFA. Whether these changes are the result of a direct effect of the CLA plus n-3  
LC-PUFA on hypothalamic neurons or are the result of the diminished WAT signalling back to the 
hypothalamus is unclear. However, levels of circulating leptin appear to be minimally lowered or 
unchanged after CLA plus n-3 LC-PUFA supplementation, ruling out WAT-derived leptin as a 
possible mechanism. However, there may be other circulating factors from WAT, not measured in the 
present study, which may signal the brain. Similarly, there is no difference in the level of circulating 
ghrelin. However, [
125I]-leptin binding to the choroid plexus was significantly increased in the 
supplemented rats indicating that the transport of leptin into the brain may be increased. Nonetheless, 
the difference was relatively small and the biological impact of such a change is unknown. Leptin acts 
as a powerful anorexigenic agent in lean animals. Increased leptin transport into the brain should not 
result in the gene changes observed in the hypothalamus or in the increased food intake exhibited. In Nutrients  2009, 1                                       
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addition, circulating adiponectin, which acts centrally to increase food intake, is reduced by 
approximately 40% with CLA plus n-3 LC-PUFA supplementation. Therefore, the drop in circulating 
adiponectin also cannot give rise to the changes in gene expression seen in the hypothalamus or the 
increased food intake.  
Decreased circulating levels of adiponectin have previously been shown in mice fed for 22 days 
with levels of CLA and fish oil similar to those used in the present study [12]. However, the fact that 
circulatory adiponectin levels were decreased at the same time as adiponectin gene expression was 
increased in the two WAT depots tested in the present study indicates that the mixture of CLA plus n-3 
LC-PUFA has a complex effect. In a previous study n-3 LC-PUFA was shown to increase adiponectin 
gene expression and adiponection protein content of WAT in ob/ob mice [33]. In contrast, CLA has 
been shown to inhibit the secretion of adiponectin from cultured rat adipocytes [34]. These findings 
taken together provide an explanation for the apparent discrepancy in the present study where a 
combination of CLA plus n-3 LC-PUFA was used.  
The increase in food intake without an associated increase in body weight may only be explained 
by an increase in energy expenditure in the CLA plus n-3 LC-PUFA treated animals. Physical activity 
measurements were not carried out in the present study, but analysis of gene expression in 
gastrocnemius muscle showed decreased levels of both GLUT4 and SREBP-1c mRNA (by 5-fold and 
10-fold, respectively) in the rats supplemented with CLA/n-3 PUFA. These results suggest that rats in 
this group did not display increased muscle locomotor activity, as increased levels of activity have 
been shown to be associated with increased expression of GLUT4 [35] and SREBP-1c [36]. This also 
means that the increased size of the BAT depot together with increased BAT UCP-1 expression 
remains as the sole potential mechanism identified in the present study whereby at least some of the 
energy is dissipated. BAT has high uptake rates for both glucose and lipids and regulates energy 
expenditure through the activation of UCP-1 which generates heat via lipid oxidation. An increase in 
BAT thermogenesis could explain the ability of the animals to eat more while maintaining their body 
weight. However, the effect of supplementation on the body temperature of the rats was not measured 
in the present study.  Whereas previous studies with CLA supplementation alone have shown 
conflicting effects of CLA on BAT size and UCP-1 expression [37-39], n-3 PUFA have been shown to 
both increase BAT UCP-1 levels [40] and to induce BAT thermogenic activity [41]. Furthermore, as 
CLA alone has been shown to suppress the expression and activity of PPARγ, [42],
 a transcription 
factor which plays a central role in the differentiation of both white and brown adipose cells [43,44], it 
seems likely that increased PPARγ expression drives BAT enlargement in the CLA plus n-3 LC-PUFA 
supplemented animals.  
CLA plus n-3 supplementation also invoked a depot specific reduction in both retroperitoneal and 
subcutaneous WAT. Such a heterogeneous reduction in adiposity has been observed in many different 
animal models and is a classical characteristic of CLA supplementation alone where it appears to be 
the result of decreased lipid accumulation within adipocytes [29]. One of the key enzymes in lipid 
metabolism is adipocyte LPL and the inhibition of LPL activity has been significantly correlated with 
the suppressing effect of CLA on lipogenesis [45]. Therefore, at least in the case of subcutaneous 
WAT, the reduction in adiposity induced by CLA plus n-3 supplementation in this depot was 
correlated with decreased LPL expression.  Nutrients  2009, 1                                       
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Taken together these data show that CLA plus n-3 LC-PUFA supplementation decreases WAT size 
without increasing liver lipid content. However, unexpectedly food intake was increased in the 
supplemented rats, which was reflected by an increase in hypothalamic orexigenic and a decrease in 
anorexigenic gene expression. This may be explained by the increase in the size of the BAT depot and 
an increase in UCP-1 activity in this tissue. As both CLA and n-3 LC-PUFA are readily available as 
supplements in humans and BAT has been identified in adult humans [46] the potential impact of 
supplementation with CLA plus n-3 LC-PUFA on human BAT remains an interesting possibility that 
requires further study. 
 
3. Experimental Section  
 
3.1. Experimental Animals and Supplementation 
 
All studies involving animals were licensed under the Animal (Scientific Procedures) Act of 1986 
and received approval from the Rowett Research Institute’s Ethical Review Committee. Male Hooded 
Lister rats (Rowett strain) aged 10 weeks were housed in groups of four per cage. Cages were then 
randomly allocated to one of two groups (n = 12 in each group) and fed isocalorific diets containing 
standard rodent laboratory chow (SDS, Essex, UK) supplemented with either 1% CLA (Clarinol G-80 
containing 760 mg CLA/g consisting of a 50:50 mixture of cis-9, trans-11: trans-10, cis-12 CLA from 
Loders Croklaan, Wormerveer, the Netherlands) plus 1% n-3 LC-PUFA (EPAX 5500TG; 280 mg 
EPA and 180 mg DHA/g from Pronova Biocare a.s. Lysaker, Norway) or 2% vegetable oil (Rathburn 
Chemicals, Walkerburn, Scotland). The oils were added to pellets and allowed to absorb. The pellets 
were then purged with nitrogen and frozen at –20 °C, to prevent oil oxidation, until required. Animals 
were fed ad libitum and fresh food was provided every other day and uneaten food discarded. Daily 
total food intake for each cage was recorded. Food spillage was also measured. There was no evidence 
of differential spillage between the diets. Animals were weighed three times per week. After 12 weeks, 
rats were killed by stunning and cervical dislocation prior to decapitation. Trunk blood was collected 
into heparin coated tubes and centrifuged at 1,000 g and stored at –80 °C until required. The WAT 
depots; epididymal, retroperitoneal, subcutaneous, mesenteric and omental as well as BAT, liver and 
the gastrocnemius and soleus muscles were dissected, weighed and frozen in liquid nitrogen and stored 
at –80 °C. The whole brain was removed and frozen on dry ice and stored at –80 °C.  
 
3.2. Plasma and Liver Lipids, Glucose and Circulating Liver Enzymes 
 
All measurements including circulating levels of aspartate aminotransferase (AST) and lactate 
dehydrogenase (LDH) were carried out by Analytical Services at the Rowett Institute of Nutrition and 
Health, using a Thermo Konelab 30 clinical analyser and the appropriate kits supplied by Thermo 
Kone (Manchester, UK). Liver lipids were extracted and measured using a chloroform/methanol 
extraction according to the method of Bligh and Dyer [24].  
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3.3. Semi Quantitative RT-PCR 
 
Total RNA was isolated using tissue depots, from three representative animals from each treatment, 
using Trizol (Invitrogen, Paisley, UK) according to the manufacturers’ instructions. RNA integrity and 
concentration were measured using the Agilent bioanalyser (Agilent Technologies UK Ltd, Stockport, 
UK). cDNA was prepared using the Protoscript cDNA synthesis kit (ABgene, Epsom, UK) using 1μg 
total RNA and a 2720 thermocycler (Applied Biosystems, Warrington, UK). Genes were amplified 
using the following primers: β-actin (forward primer: 5’-AGC ACA ATG AAG ATC AAG AT, 
reverse primer: 5’-TGT AAC GCA ACT AAG TCA TA); uncoupling protein-1 (UCP-1) (forward 
primer: 5’-ATA CTG GCA GAT GAC GTC CC, reverse primer: 5’-ATC CGA GTC GCA GAA AAG 
AA); lipoprotein lipase (LPL) (forward primer: 5’- CCT GAA GAC TCG CTC TCA GA, reverse 
primer: 5’-TTG GTT TGT CCA GTG TCA GC);  hormone sensitive lipase (HSL) (forward primer: 
5’-AGG ACA CCT TGG CTT GAG CG, reverse primer: 5’-TGC CCA GGA GTG TGT CTG AG); 
peroxisome proliferator-activated receptor-γ (PPARγ) (forward primer: 5’-TGA TAT CGA CCA GCT 
GAA CC, reverse primer: 5’-GTC CTC CAG CTG GTT CGC CA); sterol regulatory element binding 
protein-1c (SREBP-1c) (forward primer: 5’-GCG GAG CCA TGG ATT GCA C, reverse primer: 5’-
CTC TTC CTT GAT ACC AGG CCC); Adiponectin (forward primer: 5’-GGA ACT CGA GTG TCA 
CGA TG, reverse primer: 5’-TGG CAG CCT TCA GGA ACC CT); GLUT4 (forward primer: 5’-TCT 
CGG TGC TCT TAG TAG, reverse primer: 5’-CCA ATC TCA AAG AAG GCC ACA AA). All 
genes were amplified by heating at 94 °C, for 4 min, then 94 °C for 45 sec, 60 °C for 45 sec, 72 °C for 
45 sec, for 25 cycles (β-actin), for 30 cycles (UCP-1, LPL, HSL), for 40 cycles (Adiponectin, GLUT4) 
or for 50 cycles (PPARγ), except SREBP-1c which was amplified by heating at 94 °C for 4 min, then 
94 °C for 45 sec, 52 °C for 45 sec, 72 °C for 45 sec, for 30 cycles. PCR products of the predicted size 
were quantified on agarose gels using the UviPhoto gel documentation system (Uvitec Ltd, 
Cambridge, UK) and AIDA software (Raytest, Straubenhardt, Germany). For each amplified sequence, 
the number of PCR cycles was previously determined to lie within the linear range (data not shown). 
For normalization, β-actin levels were used as an internal control. 
 
3.4. In Situ Hybridization 
 
Specific probes for GHS-R, Ob-R, Ob-Rb, AgRp, NPY, CART and POMC were used as detailed 
previously [25-27]. Automated sequencing was performed to verify each sequence. Messenger RNA 
levels were quantified using [
35S] labelled riboprobes and in situ hybridisation,
 on 20µm thick coronal 
hypothalamic sections, using techniques
 described in detail elsewhere [28].
 Briefly, slides were fixed in 
4% (w/v) paraformaldehyde in phosphate buffered saline (PBS) (0.1 mol/L phosphate buffer/0.9% 
(w/v) saline) for 20 min at room temperature, washed in PBS, incubated in 0.1 mmol/l triethanolamine 
for 2 min and acetylated in 0.1 mmol/L triethanolamine and 0.25% (v/v) acetic anhydride for 10 min. 
Sections were dehydrated in ethanol and dried under vacuum before hybridisation with [
35S]-labelled 
riboprobes at 10
6 cpm/ml for 18 h at 58 °C. After hybridisation, sections were desalted through a series 
of washes in standard saline citrate (SSC) to a final stringency of 0.1 X SSC at 60 °C for 30 min, 
treated with RNase A and dehydrated in ethanol. Slides were apposed to Biomax MR (Sigma, Poole, Nutrients  2009, 1                                       
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Dorset, UK) together with [
14C] micro-scale standards (Amersham International, Amersham, UK) at 
room temperature for varying lengths of time depending on the probes used.  
 
3.5. In vitro Autoradiography 
 
Sections were acid prewashed in low pH, high salt (pH 2, 0.5M NaCl) HEPES buffer, to remove 
any endogenous leptin bound to its receptor, prior to a brief wash in HEPES before incubation with 
1nM [
125I]leptin with the specific activity adjusted to 250,000 cpm/pM in HEPES for 2 h at room 
temperature. Control slides were incubated with [
125I]leptin as above plus 1μM leptin. Slides were then 
thoroughly washed in HEPES buffer followed by distilled water at 4°C and air dried before apposed to 
Biomax MR (Sigma, Poole, Dorset, UK) together with [
125I] micro-scale standards (Amersham 
International, Amersham, UK) at room temperature. 
 
3.6. Quantification of in situ Hybridisation and in vitro Autoradiography 
 
Autoradiographs were scanned on a Umax Power Look II (UMAX Data Systems, Fremont, CA, 
USA). Integrated optical densities (IOD), a measurement of both surface area and optical density of 
images, were quantified using the Image Pro-plus system (Media Cybernetics, Silver Springs, MD, 
USA) and converted to nCi/g
 using [
14C] microscale standard curves. For quantification of [
125I]leptin 
binding to the choroid plexus, average optical densities were measured. Average optical densities were 
converted to nCi/g
 using [
125I] microscale standard curves. 
 
3.7. Plasma Hormones 
 
Serum leptin and ghrelin concentrations were measured using commercially
 available rat-specific 
radioimmunoassay kits (Linco Research Inc., St. Charles, MI, USA and Phoenix Diagnostics Inc., 
Belmont, CA, USA, respectively). Adiponectin was measured by ELISA (B-Bridge International,   
CA, USA). 
 
3.8. Statistical Analysis 
 
Data are represented as mean ±  SEM and were analysed by one-way ANOVA. P  = 0.05 was 
considered statistically significant.  
 
4. Conclusions  
 
This study shows that the CLA plus n-3 LC-PUFA supplementation is effective in decreasing WAT 
deposition without an increase in liver lipid. Unexpectedly this decrease in WAT was accompanied by 
an increase in food intake. The increase in food intake appears to be due to an increase in hypothalamic 
orexigenic and a decrease in anorexigenic gene expression. The increased food intake does not result 
in an increase in body weight due to activation of BAT. This is particularly important when the 
occurrence and function of BAT in adult humans has been identified [46]. Further studies are required Nutrients  2009, 1                                       
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to identify how the combination of CLA plus n-3 LC-PUFA drives these changes in the hypothalamus 
and BAT. 
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